Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Sezary Syndrome 1Sarcoma, Synovial 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mycosis Fungoides 1Liposarcoma, Myxoid 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1Carcinoma 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Paclitaxel 57Carboplatin 51Bevacizumab 41Taxes 28liposomal doxorubicin 21Gemcitabine 19Immunoglobulin G 17Disulfides 17pembrolizumab 15Topotecan 12rucaparib 10Cyclophosphamide 9Cisplatin 9Docetaxel 8olaparib 7Doxorubicin 7pazopanib 6mirvetuximab soravtansine 6cediranib 6Nivolumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5sargramostim 4niraparib 4Surgical Procedures, Operative 4Drug Therapy 4Cytoreduction Surgical Procedures 4Albumin-Bound Paclitaxel 4veliparib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Neoplasms × interferon gamma-1b × Clear all
NCT02948426 2026-01-08

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
18 enrolled 19 charts
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡